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in the assumptions.CONCLUSIONS:Comparedwith usual therapeutic strategies of
anemia, the use of intravenous iron appears to be significantly cost saving in che-
motherapy-induced anemia in breast cancers and gastrointestinal cancers.
PCN29
TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) USING RITUXIMAB
(R) WITH FLUDARABINE (F) AND CYCLOPHOSPHAMIDE (C): ASSESSING THE
FINANCIAL IMPACT OF THE ROUTE OF ADMINISTRATION AT PRINCESS
MARGARET HOSPITAL (PMH)
Douglas P1, Lee R2, Worthington K1, Mistry B1
1Hoffmann-La Roche Limited, Mississauga, ON, Canada, 2University Health Network, Toronto,
ON, Canada
OBJECTIVES: The objective of this study was to determine, from the perspective of
PMH, the financial impact of treating patients with CLL using R and intravenous FC
(R-FC IV) versus R and orally administered FC (R-FC PO).METHODS: A cost analysis
was performed from the perspective of PMH. All drug and administration costs
were obtained from relevant sources in the province of Ontario and validated by
PMH. Rituximab dosing was set at 375 mg/m2 for cycle 1 (day 1) and 500 mg/m2 of
cycles 2-6 (day 1). Intravenous F and C were dosed at 25 mg/m2 and 250 mg/m2,
respectively, for 6 cycles (days 1-3). Oral dosing of these drugs was set at 40 mg/m2
and 325 mg/m2, respectively. Drug utilization was estimated based on a body sur-
face area of 1.8 m2. RESULTS: The cost of R-FC PO at PMH is $32,634 per patient
(Drug cost: $29,292; Administration cost: $3,342), while the cost of R-FC IV is $33,400
per patient (Drug cost: $25,192; Administration cost: $8,208). Overall, utilization of
R-FC PO is $766, or 2%, less costly than R-FC IV at PMH. Real-world conditionswould
impact the difference in price between these two options, as patients may tolerate
more treatment cycles of one regimen compared to another. The cost of the PO and
IV routes of administration may be viewed as functionally equivalent at PMH,
making the decision to employ a specific route of administration one that should be
based on non-financial criteria. These results should apply to all Canadian hospi-
tals with drug and administration costs that are similar to those found at PMH.
CONCLUSIONS:This analysis shows that R-FC PO ismarginally less expensive than
R-FC IV at PMH. Therefore, the choice of format should bemade based on patients’
individual needs.
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DOES A LACK OF HTA REVIEW LEAD TO HIGHER PRICES FOR HIV
TREATMENTS? A COMPARISON WITH ONCOLOGY TREATMENTS
Nordyke R1, Imbeah-Ampiah R2, Ng-Haing J2, Oshinowo B2, Saraf S2
1PriceSpective LLC, El Segundo, CA, USA, 2PriceSpective Ltd., London, UK
OBJECTIVES: Therapies for HIV and cancer draw attention due to both high unmet
need and high costs. In some cases, HIV treatments are approaching the prices of
cancer treatments. However these disease states are often reviewed differently by
payers and HTA agencies. NICE, for example, does not perform HTAs for HIV ther-
apies while other European countries do. We examined the relative differences in
prices between HIV and cancer therapies across several European countries to
identify the potential impact of HTA reviews. METHODS: We included therapies
approved for use 2004-2010 in HIV (Atripla, Trizivir, Reyataz, Norvir, Truvada, In-
virase, Celsentri, Isentress, Fuzeon) and cancer (Alimta, Avastin, Erbitux, Sutent,
Tyverb,Taxotere, Nexavar). Current yearly treatment prices (2010) were identified
for all therapies for UK, FR, DE, IT, and ES. Price differentials between the UK and
other countries were determined for each treatment. Mean country price differen-
tials (UK reference) were compared. RESULTS: HIV therapies were on average 30%
(median differential 29%) lower in price in the UK than other countries. Price dif-
ferentials for HIV therapy ranged from 18% (higher price in UK) to 75% (less
expensive in UK). Cancer therapy prices averaged 36% (median 36%) lower in UK
than other countries. Price differentials for HIV therapy ranged from 6% to 80%
(lower price in UK) with amedian of 36%. The apparent discrepancy betweenmean
country differentials was not present if the single HIV therapywasmore expensive
in the UK than other European countries (Norvir was excluded). CONCLUSIONS:
Across 9 HIV therapies and 7 cancer treatments, all treatments were on average
lower in price in the UK. However, the price differential was not substantially
different across the 2 therapy areas. There is little evidence supporting an upward
price pressure due to a lack of economic-driven HTA reviews of HIV products when
compared to oncology therapies.
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DIRECT MEDICAL COSTS OF ELDERLY PATIENTS WITH STAGE III COLON
CANCER DURING FIRST-LINE VERSUS SECOND-LINE CHEMOTHERAPY
Yang HK, Bikov K, Onukwugha E, Mullins CD
University of Maryland School of Pharmacy, Baltimore, MD, USA
OBJECTIVES: Economic analyses of stage III colon cancer (CC) treatments should
account for multiple lines of chemotherapy, yet little is known about the cost
variation between first-line (1stTx) and second-line chemotherapy (2ndTx). This
study investigates the direct medical costs of 1stTx and 2ndTx among elderly
American patientswith stage III CC.METHODS:We included patients over 65 years
and diagnosed with stage III CC from the 1997-2005 Surveillance, Epidemiology,
and End Results (SEER)-Medicare database. 1stTx was defined as any use of 5-flu-
orouracil/leucovorin-only, oxaliplatin-based, or irinotecan-based chemotherapies;
2ndTx was the chemotherapy following the 1stTx after a therapy gap of at least 12
weeks or a switch in chemotherapy. 1stTx and 2ndTx were examined during the
first 40 weeks following chemotherapy initiation. Cost data representing total
Medicare reimbursements were used to calculate weekly costs for the first 26
weeks of each treatment. We further examined the cost difference between pa-
tientswho started 2ndTx early (26weeks) and late (26weeks). RESULTS:Among
18,378 elderly patients with stage III CC, 57% received 1stTx (n10,408). Among
1stTx users, 8% (n870) went on to receive 2ndTx. Average weekly total medical
costs for 1stTx varied between $647 and $1,493 (meanSD$895166) while these
for 2ndTx were higher, ranging from $752 to $2,041 (meanSD$1,046286). Fur-
thermore, average weekly total medical costs of 2ndTx in patients who started
2ndTx early ranged from $900 to $2,093 (meanSD$1,251318), reflecting higher
costs than among late 2ndTx users, whose costs ranged from $767 to $1,483
(meanSD$1,011226). CONCLUSIONS: Average weekly total medical costs of
stage III CC patients were higher for 2ndTx than 1stTx. Early 2ndTx initiators also
had higher average weekly total medical costs than late 2ndTx users. Findings
suggest that directmedical costs of stage III CC patients are lowerwhen they are on
first-line than second-line chemotherapy.
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COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS
AND COSTS IN CHRONIC KIDNEY DISEASE AND CHEMOTHERAPY-INDUCED
ANEMIA OUTPATIENTS
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OBJECTIVES: To compare erythropoiesis-stimulating agent (ESA) dosing patterns
and costs in outpatients with chronic kidney disease (CKD) not on dialysis or with
chemotherapy-induced anemia (CIA).METHODS: Electronic records from the Pre-
mier Perspective Comparative Hospital Database (2006Q1-2009Q3) were analyzed
to identify outpatients18 years old treated with epoetin alfa (EPO) or darbepoetin
alfa (DARB). Patients receiving renal dialysis or treated with both ESAs were ex-
cluded. CKDpatients had1 claim for CKD, no claim for cancer, and did not receive
chemotherapy. CIA patients had1 claim for cancer, received chemotherapy, and
had no claim for CKD. The mean cumulative ESA dose was used to calculate costs,
based on April 2010 wholesale acquisition costs (EPO: $15.15/1,000 Units, DARB:
$4.96/mcg). RESULTS: A total of 11,012 CKD (EPO: 6,921; DARB: 4,091) and 5,590 CIA
(EPO: 2,856; DARB: 2,734) outpatients were identified. EPO patients were slightly
younger than DARB patients in the CKD group (years: 71.0 vs. 71.6; P.0341) and of
similar age in the CIA group (years: 62.2 vs. 62.7; P.1316). The proportion of fe-
males was higher in CKD (EPO 62.2% vs. DARB 58.8%; P.0003) and smaller in CIA
(EPO 63.4% vs. DARB 67.0%; P.0047). The mean treatment duration was slightly
longer for EPO CKD patients (months: 3.6 vs. 3.4, P.0004) and similar for CIA
patients (months: 2.6 vs. 2.5; P.1816). Themean cumulative dose was EPO 137,101
Units and DARB 533 mcg in CKD, and EPO 221,652 Units and DARB 933 mcg in CIA,
yielding dose ratios of 257:1 and 238:1 (Units EPO:mcg DARB), respectively. Corre-
sponding ESA costs were higher for DARB than for EPO in both populations (CKD:
$2,644 vs. $2,077; CIA: $4,627 vs. $3,358). CONCLUSIONS: This analysis reported
dose ratios of 257:1 and 238:1 in CKD and CIA outpatients, respectively. DARB price
premiums of 27% for CKD and 38% for CIA patients were observed.
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COST SAVINGS ASSOCIATED WITH TRANSFUSION INDEPENDENCE IN
PATIENTS WITH MYELODYSPLASTIC SYNDROME WITH A 5Q- DELETION
Bozkaya D1, Mahmoud D2, Mitsi G3, Khan ZM2
1United BioSource Corporation, Lexington, MA, USA, 2Celgene, Summit, NJ, USA, 3United
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OBJECTIVES: Red blood cell transfusion is the standard of care for many patients
with myelodysplastic syndrome (MDS) in the US. Transfusions are economically
burdensome due to the costs associated with the transfusions including iron che-
lation therapy (ICT). This study aimed to investigate potential cost savings associ-
ated with transfusion independence as a result of lenalidomide use.METHODS: A
one-year simulation model was constructed to estimate the relevant costs of using
lenalidomide compared to transfusions in the treatment of MDS patients with a 5q-
deletion and transfusion-dependent anemia. A two arm model was constructed to
simulate patients through the costs of lenalidomide vs. transfusions. Patients were
assigned initial transfusion and ICT requirements, response status, risk of infection,
death, progression to acutemyeloid leukemia (AML), and iron overload complications
(IOC) based on data from a clinical trial and existing literature. Patients who became
transfusion independent were subject to lower risk of infection, death, progression to
AML and elimination of ICT. Dosing frequency andmodification of lenalidomide was
simulated based on results of the MDS-003 clinical trial. Treatment guidelines also
served as a basis of assumptions when required. Resource use and cost data (in 2010
US dollars) were obtained from US databases and available literature. RESULTS: In a
scenario where it was assumed that patients became transfusion independent with
lenalidomide use, a patient’s cost was $119,186 inclusive of the cost of lenalidomide,
whereas the costs for a transfusion dependent patient were $77,729. In this scenario,
patients receiving lenalidomide experienced reduced infections, IOCs, progression to
AML and ICT compared to patients treated with transfusions. CONCLUSIONS: In the
US, treatingMDSpatientswith transfusion-dependent anemia and a 5q-deletionwith
lenalidomide results in cost savings due to a reduction in costs from transfusion re-
lated complications. These savings serve to largely offset lenalidomide treatment
costs.
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LONG-TERM DIRECT MEDICAL COSTS IN PATIENTS DIAGNOSED WITH
FOLLICULAR LYMPHOMA WHO RECEIVE FRONTLINE CHEMOTHERAPY WITH
VERSUS WITHOUT RITUXIMAB - A SEER MEDICARE ANALYSIS
Griffiths RI1, Gleeson ML1, Mikhael JR2, Danese MD1
1Outcomes Insights, Inc., Westlake Village, CA, USA, 2Mayo College of Medicine, Scottsdale, AZ,
USA
OBJECTIVES: To compare long-term costs to Medicare in patients diagnosed with
follicular lymphoma (FL) receiving frontline chemotherapy /- rituximab.
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METHODS: Using Surveillance, Epidemiology, and End Results (SEER) cancer regis-
try data linked to Medicare claims, we identified 1,117 FL patients diagnosed be-
tween 01/99 and 12/05. Patients were included if chemotherapy began within 90
days of cancer diagnosis and consisted of CHOP (cyclophosphamide [C], doxorubi-
cin, vincristine [V], and prednisone [P]) or CVP rituximab. Monthly Medicare paid
amounts were calculated for each of 48 monthly partitions following chemother-
apy initiation. To account for censoring we conducted 48 inverse probability-
weighted (IPW) least-squares regression analyses to examine patient factors asso-
ciated with cumulative costs after each partition. Total costs were divided into
chemotherapy and non-chemotherapy. Overall survival was estimated using Ka-
plan-Meier analysis. RESULTS: The median age was 73 years, 56% were diagnosed
with stage III-IV disease, 67% received rituximab, and, among these, the average
cost of rituximabwas $17,958 during the first 12months of frontline therapy. In IPW
regression, the incremental cumulative total cost associated with rituximab was
$20,622 (95% Confidence Interval [CI] $16,999-$24,092) at month 6, $19,606 (95% CI
$14,996-$23,914) at month 12, and $18,122 (95% CI $8,110-$27,533) at month 48.
Other factors associated with higher costs were later cancer stage and higher co-
morbidity index. The cumulative chemotherapy cost associated with rituximab
was $18,109 (95%CI $16,081-$20,365) atmonth 6, $16,249 (95%CI $13,820-$19,023) at
month 12, and $16,130 (95% CI $11,320-$21,015) at month 48. There were no differ-
ences in cumulative non-chemotherapy costs associated with rituximab at any
time. Kaplan-Meier 48-month survival was 74.4% for rituximab and 62.6% for non-
rituximabpatients.CONCLUSIONS:Thenet cost of rituximab is consistentwith the
cost of rituximab treatment, suggesting that over 48 months additional costs from
improved survival were balanced by the reduced need for medical services.
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DOSING PATTERN AND COST COMPARISON OF EPOETIN ALFA AND
DARBEPOETIN ALFA IN CHRONIC KIDNEY DISEASE AND CHEMOTHERAPY-
INDUCED ANEMIA INPATIENTS
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OBJECTIVES: To compare erythropoiesis-stimulating agent (ESA) dosing patterns
and costs in inpatients with chronic kidney disease (CKD) not on dialysis or with
chemotherapy-induced anemia (CIA).METHODS: Electronic records from the Pre-
mier Perspective Comparative Hospital Database (2006Q1-2009Q4) were analyzed
to identify inpatients 18 years old treated with epoetin alfa (EPO) or darbepoetin
alfa (DARB). Patients receiving renal dialysis or treated with both ESAs were ex-
cluded. CKDpatients had1 claim for CKD, no claim for cancer, and did not receive
chemotherapy. CIA patients had1 claim for cancer, received chemotherapy, and
had no claim for CKD. The mean cumulative ESA dose was used to calculate costs,
based on April 2010 wholesale acquisition costs (EPO: $15.15/1,000 Units, DARB:
$4.96/mcg). RESULTS: A total of 148,746 CKD (EPO: 116,017; DARB: 32,729) and
13,832 CIA (EPO: 10,454; DARB: 3,378) patients were identified. EPO patients were
slightly younger than DARB patients in the CKD group (years: 71.0 vs. 71.2; P.0199)
and slightly older in the CIA group (years: 60.7 vs. 59.2; P.0001). The proportion of
females was higher in CKD (EPO 52.3% vs. DARB 51.3%; P.0018) and similar in CIA
(EPO 52.9% vs. DARB 53.8%; P .3722). The mean length of stay (LOS) was slightly
longer for EPO patients (days: CKD: 9.9 vs. 9.7, P.0006; CIA: 13.4 vs. 12.6; P.0028).
The mean cumulative dose was EPO 37,333 Units and DARB 149 mcg for CKD pa-
tients, and EPO 62,605Units andDARB 272mcg for CIA patients, yielding dose ratios
of 251:1 and 230:1 (Units EPO:mcg DARB), respectively. Corresponding ESA costs
were higher for DARB than for EPO in both populations (CKD: $739 vs. $566; CIA:
$1,349 vs. $948). CONCLUSIONS: This analysis reported dose ratios of 251:1 and
230:1 and a cost premium associated with DARB of 31% and 42% for CKD and CIA
inpatients, respectively, despite longer LOS for EPO patients.
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COST ANALYSIS, SAFETY, AND EFFICACY OF PEMETREXED/CISPLATIN
COMPARED WITH BEVACIZUMAB/GEMCITABINE/CISPLATIN IN PATIENTS
WITH PREVIOUSLY UNTREATED ADVANCED NON-SQUAMOUS NSCLC IN
RUSSIA
Davey P1, Rajan N2, Kanivets Y3, Barraclough H2, Orlando M4, Brnabic AJ5, Han B6
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OBJECTIVES: The novel chemotherapy agent pemetrexed combined with cisplatin
and the vascular endothelial growth factor (VEGF)-targeted agent bevacizumab
combined with cisplatin and gemcitabine are approved as first-line treatments for
patients with non-squamous non-small cell lung cancer (NSCLC). Recent studies
have claimed that bevacizumab has equivalent safety and is cost-saving when
comparedwith pemetrexed in this population. This study analyzed the health care
costs in Russia based on the indirect analysis and local treatment practice. Safety
and efficacy were also compared.METHODS: As no direct head-to-head trials have
been undertaken comparing the two regimens, an indirect treatment comparison
approach was used. Data from 2 separate studies, that had a common comparator
(cisplatin/gemcitabine), were analyzed. Only the 7.5 mg bevacizumab arm was
included. The cost analysis comprised chemotherapy and adverse event treatment
costs. Chemotherapy costs were based on the average number of cycles in the
trials. Safety and efficacy endpoints were matched from the available data. Previ-
ous studies had assumed equivalent safety and used median number of cycles for
the calculation of drug costs when the cycles of bevacizumab are not normally
distributed. RESULTS: The overall proportion of patients suffering a severe adverse
event was significantly lower with pemetrexed (10.50; 95%CI 18.4, 2.71). No
significant differences were found in overall survival (HR 0.90; 95%CI 0.72, 1.13),
although in the individual trials only pemetrexed demonstrated significant sur-
vival advantage (HR 0.84; 95%CI 0.74, 0.96) while 7.5 mg bevacizumab showed no
survival advantage (HR 0.93; 95%CI 0.78, 1.11). When costs were based on the aver-
age number of cycles used on a per-patient basis (4.3 vs. 7.2), pemetrexed was
cost-saving (saving R337,600 or $US11,100) with most savings from chemotherapy
costs to pharmacy (R334,100 or $US10,900). CONCLUSIONS: Pemetrexed is cost-
saving and less toxic compared to bevacizumab in this patient population, and
produces at least equal survival outcomes.
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ESTIMATING COST OF TREATMENT IN ELDERLY PATIENTS WITH COLORECTAL
CANCER USING MEDICARE DATA
Kokkotos F, Shen S, Wang Z, Zhang Y
Trinity Partners, LLC, Waltham, MA, USA
OBJECTIVES: Coloretal cancer (CRC) is one of the most common and costly cancer
in the United States. 70% of the patients are diagnosed post 65 years old. This study
used a large cohort of patients from 2005-2008 100% Medicare Institutional Inpa-
tient and Outpatient data to estimate the cost of different treatments and under-
stand the chemotherapy use for CRC patients. METHODS: 203,532 (50.8% Female)
CRC patients that were age 65 or older with a mean Charlson Comorbidity Index
(CCI) of 2.30 ( 3.26) were identified by ICD-9 code 153.x and/or 154.x. The overall
cost for patient groups with different characteristics was compared by using stan-
dard t-test,Wilcoxon test or ANOVA. The costwas furthermodeled in a generalized
linear model (GLM) with a log-link and gamma distributed variance functions.
RESULTS: 38% of CRC patients had surgery, 6.0% conducted radiotherapy and 5.7%
received chemotherapy. Patients on chemotherapy were incurred with the highest
cost ($41,867), followed by radiotherapy ($13,812) and surgery ($4,964). Patients on
5-FU, Leucovorin, Oxaliplatin and Bevacizumab (5-L-O-B) had the highest esti-
mated cost ($52,158), as its patient populationwas themost severe (Mean CCI7.6),
followed by 5-FU, Leucovorin and Oxaliplatin (5-L-O) ($39,435, Mean CCI4.6). The
average cost for other chemotherapies was $30,838. Most colon cancer patients
(2,761 patients) used the drug combination of 5-L-O and 5-L-O-B (1,450 patients).
Oxaliplatin and Bevacizumab were administered at a lower dose when used in
combination with other drugs than used alone. About 60% of the patients received
these combinations as adjuvant therapy after surgery. CONCLUSIONS: This study
provided information on the average annual cost of elderly CRC patients by treat-
ment type and disease comobidity. The analysis illustrated the utilization of che-
motherapy in CRC treatment: the common drug combinations and its costs, dosing
and administration information as well as chemotherapy use after surgery.
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FIRST-YEAR COSTS FOR THE 19 MOST COMMON CANCER DIAGNOSES IN
ONTARIO
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OBJECTIVES: The first year after cancer diagnosis is a period of intensive treatment
and high cost. Our objective is to estimate the first year costs for patients initially
diagnosed with one of the 19 most common cancers in Ontario between 1997 and
2007. METHODS: We selected patients who were diagnosed at 19 years of age or
older, with valid ICD-O and histology codes, who survived more than 30 days after
diagnosis, and had no second cancer within 90 days of the initial cancer from the
Ontario Cancer Registry (N 412,787). We linked these patients to health care ad-
ministrative databases, and radiation therapy data from Cancer Care Ontario. We
defined the health care resources to be costed and developed suitable costing
methodologies. We examined health care resource use and calculated mean costs
for each type of cancer in the first year after diagnosis. RESULTS: Patients with
myeloma and brain cancer incurred the highest mean first-year costs ($71,892
and $65,629, respectively); patients with melanoma, uterine and prostate can-
cers had the lowest mean costs ($21,050, $29,115 and $29,309 respectively). The
most costly resources for all cancer types were hospitalizations (38% of total
costs) and physician services (28% of total costs). Surprisingly, chemotherapy
and radiation therapy contributed very little to the total (4% and 1%, respec-
tively). Previous research on first-year costs for patients aged 65 in the US also
found that brain and other nervous system cancers had the highest cost of care
while melanoma of the skin had the lowest cost; hospitalization was also the
costliest resource. CONCLUSIONS: The first-year costs of cancer care in Ontario
are substantial and vary by tumour site. Hospitalizations and physician services
comprise a large portion of the costs for all cancer types. These estimates will
improve the quality of future cancer-related economic evaluations and are of value
to researchers and policy makers.
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COSTS AT THE END OF LIFE FOR PATIENTS WITH CASTRATION-RESISTANT
PROSTATE CANCER (CRPC)
Alemayehu B1, Parry D2, Engel-Nitz NM3, Kulakodlu M3, Nathan F1
1AstraZeneca, Wilmington, DE, USA, 2AstraZeneca, Macclesfield, Cheshire, UK, 3i3 Innovus,
Eden Prairie, MN, USA
OBJECTIVES: Recent research describes decreasing quality of life for patients with
CRPC at the end of life, but less is known about accompanying changes in health
care costs. This study aimed to examine costs at the end of life for patients with
CRPC who died compared to patients alive at the end of the study period.
METHODS: A retrospective study design used medical and pharmacy claims and
lab results (2001-2007) to identify patients with CRPC from a large U.S. managed
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